
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's financial projections indicate substantial growth, with product sales anticipated to increase from $1.73 billion in 2025 to $2.15 billion in 2026, reflecting strong demand for its multiple mRNA candidates. The company has also bolstered its financial standing through a $1.5 billion debt deal, which provides enhanced flexibility for navigating uncertainties and capitalizing on future opportunities. Moreover, improvements in manufacturing efficiency are expected to restore gross margins to approximately 50%, up from a pandemic low of 30%, potentially driving further profitability in the years ahead.
Bears say
Moderna is experiencing significant revenue declines, with COVID vaccine sales projected at $6.7 billion for 2023, a substantial drop from $18 billion in 2022, driven by waning vaccination rates and increasing competition in the respiratory vaccine landscape. The company has adjusted its long-term revenue outlook for COVID-related products from $3.5 billion to $2.5 billion annually, exacerbated by low sales expectations in the European market and slow progress in its pipeline outside of respiratory vaccines. As a result, the valuation of its COVID and COVID+flu vaccines has been reduced from $11.70 billion to $10.50 billion, reflecting ongoing uncertainty and material short-term headwinds.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares